Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Advisory Board Co. (The) ABCO NASDAQ

NASDAQ • Healthcare • Health Care Equipment & Supplies • USD

SharesGrow Score
66/100
1/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Advisory Board Co. (The) (ABCO) is a Health Care Equipment & Supplies company in the Healthcare sector, currently trading at $0.90. It has a SharesGrow Score of 64/100, indicating a above average investment profile with 1 out of 7 criteria passed.

Financials: revenue is $803M, +32.2%/yr average growth. Net income is $91M, growing at -157.6%/yr. Net profit margin is 11.4% (healthy). Gross margin is 51.1% (+6 pp trend).

Balance sheet: total debt is $522M against $517M equity (Debt-to-Equity (D/E) ratio 1.01, moderate). Current ratio is 1.01 (adequate). Debt-to-assets is 25.6%. Total assets: $2.0B.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 75/100 (Partial), Health 50/100 (Partial), Moat 58/100 (Partial), Future ?/100 (Fail), Income 55/100 (Partial).

ABCO SharesGrow Score Overview

66/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 75/100
strong — trend
HEALTH 50/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 58/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 55/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ABCO

✓
VALUE Pass
100/100
ABCO trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
ABCO: +32.2%/yr revenue is, -157.6%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
~
PAST Partial
75/100
ABCO: 3 / 4 years profitable. mixed. Score = 3 / 4 × 100. ≥ 80 = Pass.
View details →
~
HEALTH Partial
50/100
Balance sheet ABCO: Debt-to-Equity (D/E) ratio 1.01 (moderate), Current ratio is 1.01 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
58/100
ABCO: Gross margin is 51.1% (+6 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 58/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
~
INCOME Partial
55/100
ABCO: Net profit margin is 11.4%. thin (5-15%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.95-0.63
Volume10.2K
Avg Volume (30D)4.87K
Beta (1Y)-8.33
Share Statistics
EPS (TTM)2.23
Shares Outstanding$40.87M
IPO Date2000-03-27
Financial Highlights & Ratios
Revenue (TTM)$803.42M
Gross Profit$410.47M
EBITDA$198.62M
Net Income$91.24M
Operating Income$76.54M
Total Cash$111.01M
Total Debt$522.09M
Net Debt$430.94M
Total Assets$2.04B
Price / Earnings (P/E)0.4
Analyst Forecast
Company Info
ExchangeNASDAQ
CurrencyUSD

Price Chart

Track all markets on TradingView
ABCO
Advisory Board Co. (The)  ·  NASDAQ
Healthcare • Health Care Equipment & Supplies

People Also View

LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
 RHHBF
RHHBF
Roche Holding AG
$418.50
+1.82%
 RHHBY
RHHBY
Roche Holding AG
$51.02
+0.65%
 AZN
AZN
AstraZeneca PLC
$204.38
+1.06%
 NVSEF
NVSEF
Novartis AG
$156.48
+0.00%
 MRK
MRK
Merck & Co., Inc.
$119.96
-0.16%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message